Eric J. Small
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Prostate Cancer Treatment and Research 372
- Prostate Cancer Diagnosis and Treatment 82
- Oncology 172
- Cancer Immunotherapy and Biomarkers 58
- Cancer Treatment and Pharmacology 37
- Co-authors
- Susan Halabi (114 shared papers)Philip W. Kantoff (54 shared papers)Celestia S. Higano (44 shared papers)Brian I. Rini (42 shared papers)Paul F. Schellhammer (14 shared papers)Nicholas J. Vogelzang (50 shared papers)Mark W. Frohlich (12 shared papers)Charles H. Redfern (7 shared papers)
- Journals
- Journal of Clinical Oncology (249 papers)Cancer (42 papers)The Journal of Urology (40 papers)Annals of Oncology (24 papers)Clinical Cancer Research (23 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Eric J. Small
600 papers receiving 35.2k citations
Eric J. Small's Hit Papers
Peers
Comparison fields: 5 of 150
- Pulmonary and Respiratory Medicine 21.1k
- Oncology 10.8k
- Cancer Research 5.9k
- Immunology 5.9k
- Radiology, Nuclear Medicine and Imaging 3.9k
Countries citing papers authored by Eric J. Small
This map shows the geographic impact of Eric J. Small's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric J. Small with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric J. Small more than expected).
Fields of papers citing papers by Eric J. Small
This network shows the impact of papers produced by Eric J. Small. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric J. Small. The network helps show where Eric J. Small may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric J. Small, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 617 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer Hit paper breakdown → | 2010 | 4127 |
| 2 | Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer Hit paper breakdown → | 2004 | 2885 |
| 3 | Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group Hit paper breakdown → | 2008 | 1714 |
| 4 | Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer Hit paper breakdown → | 2018 | 892 |
| 5 | Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer Hit paper breakdown → | 2006 | 849 |
| 6 | Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 Hit paper breakdown → | 2008 | 707 |
| 7 | Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer Hit paper breakdown → | 2009 | 611 |
| 8 | Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer Hit paper breakdown → | 2003 | 542 |
| 9 | Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial Hit paper breakdown → | 2017 | 512 |
| 10 | Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial Hit paper breakdown → | 2002 | 498 |
| 11 | 2000 | 497 | |
| 12 | Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. | 1999 | 467 |
| 13 | 2004 | 385 | |
| 14 | 2005 | 379 | |
| 15 | Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer Hit paper breakdown → | 2015 | 369 |
| 16 | 2006 | 367 | |
| 17 | Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401 Hit paper breakdown → | 2012 | 350 |
| 18 | Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. | 1996 | 330 |
| 19 | Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2014 | 329 |
| 20 | A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer Hit paper breakdown → | 2007 | 324 |
About Eric J. Small
Eric J. Small is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Radiology, Nuclear Medicine and Imaging, Cancer Research and Molecular Biology, having authored 617 papers that have together received 36.0k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (372 papers), Radiopharmaceutical Chemistry and Applications (115 papers), Prostate Cancer Diagnosis and Treatment (82 papers), Cancer, Lipids, and Metabolism (69 papers), Cancer Immunotherapy and Biomarkers (58 papers), Immunotherapy and Immune Responses (44 papers), Cancer Treatment and Pharmacology (37 papers) and Cancer Genomics and Diagnostics (34 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (21.1k citations), Oncology (10.8k citations), Cancer Research (5.9k citations), Immunology (5.9k citations) and Radiology, Nuclear Medicine and Imaging (3.9k citations). Eric J. Small has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Susan Halabi, Philip W. Kantoff, Celestia S. Higano, Brian I. Rini, Paul F. Schellhammer, Nicholas J. Vogelzang, Mark W. Frohlich, Charles H. Redfern, Robert Dreicer and Maha Hussain. Their work appears in journals such as Journal of Clinical Oncology, Cancer, The Journal of Urology, Annals of Oncology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.